ASH 2018 | SCRI-CAR19v1 in R/R ALL patients who proceeded to HCT: long-term follow-up
In this interview, Corinne Summers, MD, of the Seattle Children’s Research Institute, Seattle, WA, speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, on the PLAT-02 trial (NCT02028455). This long-term follow-up of the pediatric and young adult acute lymphoblastic leukemia (ALL) patients examined the potential benefit of consolidative hematopoietic cell transplant (HCT) following SCRI-CAR19v1 treatment. Dr Summers reveals a trend towards improved leukemia-free survival (LFS) for patients without a history of HCT, and explains that HCT appeared to benefit those who attained a complete remission. However, these patients had a higher risk of relapse with short-term B-cell aplasia. Dr Summers disccuses the implications, outlook and overall goal in the maintenance of remision status for the long-term.
Get great new content delivered to your inboxSign up